Deficiencies in Traditional Oral Dosage Forms and the Emergence of Controlled-Release Powder Manufacturing
Source abstract
Abstract
The importance of providing safe and effective delayed- and extended-release oral formulations that can replace products requiring multiple administrations has been continually cited as an area in need of improvement for pharmaceutical companies. Such controlled release challenges become especially critical when they must be adapted for paediatrics, those suffering from dysphagia, or patients with specific dosage administration limitations. More often than not, lack of palatability and taste-masking compound this formulation challenge. Many particulate approaches show promise, but can be fraught with broad particle size distributions, initial drug burst, poor drug entrapment efficiency, low drug loading, and limited scalability. Here, we summarize the key factors that drive formulation development of format-flexible controlled-release oral powders, and the manufacturing aspects involved with some of the foremost marketed products, including next-generation single-step layered powder manufacturing (below).
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Pharmaceutical studies and practices · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Orbis Biosciences, Inc., USA
Department of Pharmaceutical Chemistry, University of Kansas, USA
References (56)
Show source-provided references
1. Best pharmaceuticals for children act, Public Law 107–109, Washington, DC, 2002.
2. Ambike A.A., Mahadik K.R., Paradkar A., Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug: In vitro and in vivo evaluations, Pharmaceutical Research, 22 (2005) 990–998.10.1007/s11095-005-4594-z ↗
3. Appel L., Friesen D.T., Lachapelle E.D., Konagurthu S., Falk R.F., Reo J.P., Taste-masked drugs in rupturing multiparticulates, Google Patents, https://www.google.com/patents/US8236349 (2012).
4. Appel L., Ray R., Newbold D., Lyon D., West J., Friesen D., Mccray S., Crew M., Lo J., Controlled release multiparticulates formed with dissolution enhancers, Google Patents, https://www.google.com/patents/US20050152982 (2005).
5. Bergstrom D., Mcnally E., Freeman S., The growing pediatrics market, Pharmaceutical Executive, (2004).
6. Berkland C., Pollauf E., Raman C., Silverman R., Kim K., Pack D.W., Macromolecule release from monodisperse PLG microspheres: Control of release rates and investigation of release mechanism, Journal of Pharmaceutical Sciences, 96 (2007a) 1176–1191.10.1002/jps.20948 ↗
7. Berkland C., Pollauf E., Varde N., Pack D.W., Kim K., Monodisperse liquid-filled biodegradable microcapsules, Pharmaceutical Research, 24 (2007b) 1007–1013.10.1007/s11095-006-9197-9 ↗
8. Berkland C., Singh M., Sustained release particle formulations, Google Patents, https://www.google.com/patents/US20140294980 (2014).
9. Berkland C., Singh M., Taste masking drug formulations, Google Patents, https://www.google.com/patents/WO2015130760A1?cl=en (2015).
10. Berkland C., Singh M., Dormer N., Tramadol particle formulations and methods, Google Patents, https://www.google.com/patents/WO2014205228A1?cl=en (2014).
11. Bhardwaj S., Hayward M., Palatable pharmaceutical compositions, SmithKline Beecham Corporation, (1996).
12. Cloupeau M., Prunet-Foch B., Electrohydrodynamic spraying functioning modes: A critical review, Journal of Aerosol Science, 25 (1994) 1021–1036.10.1016/0021-8502(94)90199-6 ↗
13. Cram A., Bartlett J., Heimlich J., Oral multiparticulates as a flexible solid dosage form approach for paediatric use, Bio- Pharm Asia, (2013).
14. Dewettinck K., Huyghebaert A., Fluidized bed coating in food technology, Trends in Food Science & Technology, 10 (1999) 163–168.10.1016/S0924-2244(99)00041-2 ↗
15. Dickens D.S., Sinsabaugh D., Fahner J.B., Characteristics of pediatric chemotherapy medication errors in a national error reporting database, Cancer, 112 (2008) 445–446; author reply 446.10.1002/cncr.23177 ↗
16. Eldem T., Speiser P., Hincal A., Optimization of spray-dried and -congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy, Pharmaceutical Research, 8 (1991) 47–54.10.1023/A:1015874121860 ↗
17. Elder D.P., Pharmaceutical applications of ion-exchange resins, Journal of Chemical Education, 82 (2005) 575.10.1021/ed082p575 ↗
18. Engelen L., De Wijk R.A., Van Der Bilt A., Prinz J.F., Janssen A.M., Bosman F., Relating particles and texture perception, Physiol Behav, 86 (2005) 111–117.10.1016/j.physbeh.2005.06.022 ↗
19. Fazal U.-R., Khan S.N., Therapeutic applications of ion exchange resins, in: Inamuddin D. and Luqman M. (Eds), Ion exchange technology ii: Applications, Springer Netherlands, Dordrecht, 2012, pp. 149–168.10.1007/978-94-007-4026-6_7 ↗
20. Gharsallaoui A., Roudaut G., Chambin O., Voilley A., Saurel R., Applications of spray-drying in microencapsulation of food ingredients: An overview, Food Research International, 40 (2007) 1107–1121.10.1016/j.foodres.2007.07.004 ↗
21. Gouin S., Microencapsulation: Industrial appraisal of existing technologies and trends, Trends in Food Science & Technology, 15 (2004) 330–347.10.1016/j.tifs.2003.10.005 ↗
22. Griffith R., Managing difficulties in swallowing solid medications: The need for caution., Nurse Presc, 3 (2005) 201–203.10.12968/npre.2005.3.5.19851 ↗
23. Hancock B.C., Colvin J.T., Mullarney M.P., Zinchuk A.V., Pharmaceutical powders, blends, dry granulations, and immediate- release tablets, Pharmaceutical technology, (2003) 64–80.
24. Harb J., Why so many pills are too big to swallow: And why it’s safe to crush or cut up some, but not others., (2015)
25. Hirsh J., Fleming A., Rariy R., Dosage forms using drug-loaded ion exchange resins, Google Patents, https://www.google.com/patents/US20050181050 (2005).
26. Imai E., Hatae K., Shimada A., Oral perception of grittiness, Journal of Textural Studies, 26 (1995) 561–576.10.1111/j.1745-4603.1995.tb00804.x ↗
27. Ivanovska V., Rademaker C., Van Dijk L., Mantel-Teeuwisse A., Pediatric drug formulations: A review of challenges and progress, Pediatrics, 134 (2014).10.1542/peds.2013-3225 ↗
28. Jayanthi B., Manna P., Per oral extended products – an overview, J App Pharm Sci, 1 (2011) 50–55.
29. Jono K., Ichikawa H., Miyamoto M., Fukumori Y., A review of particulate design for pharmaceutical powders and their production by spouted bed coating, Powder Technology, 113 (2000) 269–277.10.1016/S0032-5910(00)00310-7 ↗
30. Lopez F.L., Ernest T.B., Tuleu C., Gul M.O., Formulation approaches to pediatric oral drug delivery: Benefits and limitations of current platforms, Expert Opinion on Drug Delivery, 12 (2015) 1727–1740.10.1517/17425247.2015.1060218 ↗
31. Maalouf N., Developing patient-centric drug formulations to meet patient needs, (2013).
32. Matsui D., Current issues in pediatric medication adherence, Paediatr Drugs, 9 (2007) 283–288.10.2165/00148581-200709050-00001 ↗
33. Mehta K., Tu Y.H., Perumal A., Orally effective methylphenidate extended release powder and aqueous suspension product, Google Patents, https://www.google.com/patents/US8287903 (2012).
34. Milne C.P., Bruss J.B., The economics of pediatric formulation development for off-patent drugs, Clin Ther, 30 (2008) 2133–2145.10.1016/j.clinthera.2008.11.019 ↗
35. Osterberg L., Blaschke T., Adherence to medication, New Engl J Med, 353 (2005).10.1056/NEJMra050100 ↗
36. Pack D.W., Berkland C., Cox A., Kim K., Three-month, zero-order piroxicam release from monodispersed double-walled microspheres of controlled shell thickness, Journal of Biomedical Materials Research Part A, 70A (2004a) 576–584.10.1002/jbm.a.30114 ↗
37. Pack D.W., Berkland C., Kim K., PLG microsphere size controls drug release rate through several competing factors, Pharmaceutical Research, 20 (2003) 1055–1062.10.1023/A:1024466407849 ↗
38. Pack D.W., Berkland C., Kim K.K., Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions, Journal of Controlled Release, 73 (2001) 59–74.10.1016/S0168-3659(01)00289-9 ↗
39. Pack D.W., Berkland C., King M., Cox A., Kim K., Precise control of PLG microsphere size provides enhanced control of drug release rate, Journal of Controlled Release, 82 (2002) 137–147.10.1016/S0168-3659(02)00136-0 ↗
40. Pack D.W., Berkland C., Kipper M.J., Narasimhan B., Kim K.K., Microsphere size, precipitation kinetics and drug distribution control drug release from biodegradable polyanhydride microspheres, Journal of Controlled Release, 94 (2004b) 129–141.10.1016/j.jconrel.2003.09.011 ↗
41. Pande S.V., Kshirsagar M.D., Chandewar A.V., Ion exchange resins pharmaceutical applications and recent advancement, 2011, 2 (2011).
42. Passerini N., Albertini B., Perissutti B., Rodriguez L., Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel, International Journal of Pharmaceutics, 318 (2006) 92–102.10.1016/j.ijpharm.2006.03.028 ↗
43. Pediatric research equity act, Public Law 108–155, Washington DC, 2003.
44. Pharmacircle, (2016), www.pharmacircle.com, from www.pharmacircle.com.
45. Powell T.C., Controlled release potassium chloride tablet, Google Patents, https://www.google.com/patents/US5422122 (1995).
46. Regulation no. Ec 1901/2006, Ec E.P.a.T.C., Brussels, (2006).
47. Rocca J.G., Park K., Oral drug delivery: Prospects and challenges, Drug Development and Delivery, 4 (2004) No.4. http://www.drug-dev.com/Main/Back-Issues/187.aspx.
48. Sansom L., Oral extended-release products, Aust Prescr, 22 (1999) 88–90.10.18773/austprescr.1999.072 ↗
49. Sastry S.V., Nyshadham J.R., Fix J.A., Recent technological advances in oral drug delivery – a review, Pharmaceutical Science & Technology Today, 3 (2000) 138–145.10.1016/S1461-5347(00)00247-9 ↗
50. Schier J., Howland M., Hoffman R., Nelson, Fatality from administration of labetalol and crushed extended-release nifedipine, Annals of Pharmacotherapy, 37 (2003) 1420–1423.10.1345/aph.1D091 ↗
51. Sugao H., Taste masking of bitter drug powder without loss of bioavailability by heat treatment of wax-coated microparticles, Journal of Pharmaceutical Sciences, 87 (1997).10.1021/js970104g ↗
52. Tyle P., Effect of size, shape and hardness of particles in suspension on oral texture and palatability, Acta Psychologica, 84 (1993) 111–118.10.1016/0001-6918(93)90077-5 ↗
53. Vehring R., Pharmaceutical particle engineering via spray drying, Pharmaceutical Research, 25 (2007) 999–1022.10.1007/s11095-007-9475-1 ↗
54. Vummaneni V., Nagpal D., Taste masking technologies: An overview and recent updates, International Journal of Research in Pharmaceutical and Biomedical Sciences, 3 (2012) 510–525.
55. Wright D., Medication administration in nursing homes, Nurse Std, 16 (2002) 33–38.10.7748/ns.16.42.33.s1 ↗
56. Yurteri C.U., Hartman R.P.A., Marijnissen J.C.M., Producing pharmaceutical particles via electrospraying with an emphasis on nano and nano structured particles—a review, KONA Powder and Particle Journal, 28 (2010) 91–115.10.14356/kona.2010010 ↗